Abstract:Background The cerebral microvascular occlusion elicits microvascular injury which mimics the different degrees of stroke severity observed in patients, but the mechanisms underlying these embolic injuries are far from understood. The Fas ligand (FasL)-Fas system has been implicated in a number of pathogenic states. Here, we examined the contribution of microglia-derived FasL to brain inflammatory injury, with a focus on the potential to suppress the FasL increase by inhibition of the P2X 7 -FasL signaling with pharmacological or genetic approaches during ischemia. Methods The cerebral microvascular occlusion was induced by microsphere injection in experimental animals. Morphological changes in microglial cells were studied immunohistochemically. The biochemical analyses were used to examine the intracellular changes of P2X 7 /FasL signaling. The BV-2 cells and primary microglia from mice genetically deficient in P2X 7 were used to further establish a linkage between microglia activation and FasL overproduction. Results The FasL expression was continuously elevated and was spatiotemporally related to microglia activation following microsphere embolism. Notably, P2X 7 expression concomitantly increased in microglia and presented a distribution pattern that was similar to that of FasL in ED1-positive cells at pathological process of microsphere embolism. Interestingly, FasL generation in cultured microglia cells subjected to oxygen-glucose deprivation-treated neuron-conditioned medium was prevented by the silencing of P2X 7 . Furthermore, FasL induced the migration of BV-2 microglia, whereas the neutralization of FasL with a blocking antibody was highly effective in inhibiting ischemia-induced microglial mobility. Similar results were observed in primary microglia from wild-type mice or mice genetically deficient in P2X 7 . Finally, the degrees of FasL overproduction and neuronal death were consistently reduced in P2X 7 −/− mice compared with wild-type littermates following microsphere embolism insult. Conclusion FasL functions as a key component of an immunoreactive response loop by recruiting microglia to the lesion sites through a P2X 7 -dependent mechanism. The specific modulation of P2X 7 /FasL signaling and aberrant microglial activation could provide therapeutic benefits in acute and subacute phase of cerebral microembolic injury.

FasL-PDPK1 Pathway Promotes the Cytotoxicity of CD8+ T Cells During Ischemic Stroke.

Abstract TP257: Fasl Enhances Cytotoxicity of CD8 + T Cells after Ischemic Stroke

FasL Incapacitation Alleviates CD4+ T Cells-Induced Brain Injury Through Remodeling of Microglia Polarization in Mouse Ischemic Stroke.

Targeted mutation of Fas ligand gene attenuates brain inflammation in experimental stroke

FasL-Fas system and cerebral ischemia

Abstract T P222: Fasl Mutation Facilitates Double Negative T Cell Accumulation and Modulates Microglia Activation in Ischemic Stroke

Abstract TP253: Double Negative T Cells with FasL Mutation Promote M2-Microglial Polarization by Inhibiting PTPN2/TNF-α Pathway in Experimental Stroke

Abstract WP104: Neuron- Microglia Crosstalk Mediated by Soluble Fas Ligand after Ischemic Stroke

Abstract T P202: Crosstalk Between Microglia and T Cells Mediated by FasL after Cerebral Ischemia

P2X7 Signaling Promotes Microsphere Embolism-Triggered Microglia Activation by Maintaining Elevation of Fas Ligand

PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1

Double-negative T cells remarkably promote neuroinflammation after ischemic stroke

Essential Role of Program Death 1-Ligand 1 in Regulatory T-cell-afforded Protection Against Blood-Brain Barrier Damage after Stroke.

Ischemic Postconditioning Regulates New Cell Death Mechanisms in Stroke: Disulfidptosis

LCP1 Knockdown in Monocyte-Derived Macrophages: Mitigating Ischemic Brain Injury and Shaping Immune Cell Signaling and Metabolism

Cdh5-mediated Fpn1 deletion exerts neuroprotective effects during the acute phase and inhibitory effects during the recovery phase of ischemic stroke

Increased Peripheral CD137 Expression in a Mouse Model of Permanent Focal Cerebral Ischemia

Targeted therapy of brain ischaemia using Fas ligand antibody conjugated PEG-lipid nanoparticles.

Blocking Fas ligand on leukocytes attenuates kidney ischemia-reperfusion injury

Lysosomal Ca2+ release-facilitated TFEB nuclear translocation alleviates ischemic brain injury by attenuating autophagic/lysosomal dysfunction in neurons

Delayed Diapedesis of CD8 T Cells Contributes to Long-Term Pathology after Ischemic Stroke in Male Mice